封面
市場調查報告書
商品編碼
1357962

Stargardt氏症藥物市場:依藥物類型、年齡層、配銷通路、地區

Stargardt Disease Therapeuticss Market, By Drug Type (Emixustat, LBS-008, others, By Age Group (Children and Adult ), By Distribution Channel, and By Region

出版日期: | 出版商: Coherent Market Insights | 英文 167 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

預計2023年Stargardt氏症藥物的全球市場規模為2.135億美元,預測期內(2023-2030年)年複合成長率為31.7%。

報告範圍 報告詳情
基準年 2022年 2023年市場規模 2.135 億美元
實績資料 2018-2021 預測期 2023-2030
預測期年複合成長率 31.70% 2030年市場規模預測 14.672 億美元
2023 年Stargardt氏症藥物的全球市場佔有率(%)(依藥物類型)
Stargardt 疾病治療市場-IMG1

Stargardt氏症是一種由單一基因的細微變化引起的遺傳疾病。也稱為眼底黃斑,是黃斑部營養不良最常見的形式。比例萬分之一的人會發生這種情況,男性和女性罹患。 Stargard 會導致稱為黃斑部的視網膜中央部分惡化。該區域最終將被一圈白色或黃色斑點包圍。視網膜色素上皮 (RPE) 是視網膜的重要層,也會受到稱為脂褐質的「廢物」產物積聚的影響。診斷出患有斯塔加特氏症可能很困難,但只要有正確的資訊和支持,您就可以應付。重要的是要記住,在大多數情況下,患有斯塔加特病的人不會完全喪失視力。 Stargardt 病通常只影響中央視力。週邊視力通常不受影響。目前正在進行大量針對潛在治療方法的研究。因此,此類先進治療方法的引入預計將在預測期內推動全球Stargardt氏症治療市場的成長。

市場動態

醫療設備業的主要參與者致力於為各種患有Stargardt氏症的患者群開發治療方法。因此,將此類先進藥物引入市場預計將在預測期內推動全球Stargardt氏症治療市場的成長。例如,2023年6月5日,生物製藥公司Archius Pharmaceuticals宣布推出一種潛在的緩解疾病,用於治療Stargardt氏症,這是導致兒童和青少年失明的主要遺傳原因,並宣布已籌集1.5億美元B輪資金籌措支持精準醫療產品視網醇(ALK-001)的註冊和上市。資金籌措由 Bain Capital Lifesciences主導,TCGX、Wellington Management 和 Sofinova Investments 也參與其中。

本研究的主要特點

  • 該報告對全球Stargardt疾病治療市場進行了詳細分析,並提供了以2022年為基準年的預測期(2023-2030)的市場規模和年複合成長率(CAGR)。它還揭示了各個部門市場的潛在商機,並說明了市場有吸引力的投資提案矩陣。
  • 它還提供了有關市場促進因素、抑制因素、機會、新產品發布和核准、市場趨勢、區域前景、主要企業採取的競爭策略等的重要考察。
  • 它根據公司亮點、產品系列、主要亮點、業績和策略等參數,介紹了全球Stargardt氏症治療市場的主要企業。
  • 該報告的見解使行銷人員和公司負責人能夠就未來的產品發布、升級、市場擴張和行銷策略做出明智的資訊。
  • 全球Stargardt氏症治療藥物市場報告針對該行業的各個相關人員,如投資者、供應商、產品製造商、分銷商、新進業者和財務分析師。
  • 透過用於分析全球Stargardt氏症治療藥物市場的各種策略矩陣,將有助於相關人員做出決策。

目錄

第1章 調查目的和假設

  • 這項研究的目的
  • 假設
  • 簡稱

第2章 市場展望

  • 報告說明
    • 市場定義和範圍
  • 執行摘要

第3章 市場動態、法規及趨勢分析

    • 市場動態
    • 促進因素
    • 抑制因素
    • 市場機會
    • 影響分析
    • 最近測試啟動
    • 流行病學
    • 合併、收購和合作
    • 法規場景
    • 主要進展
    • PEST分析
    • 流行病學

第4章 全球Stargardt疾病治療藥物市場-新型冠狀病毒感染疾病(COVID-19)的影響分析

    • 經濟影響
    • 新型冠狀病毒感染疾病(COVID-19)的流行病學
    • 對需求和供給的影響

第5章 全球斯塔加特病藥物市場:依藥物類型,2018-2030

  • Emixustat
  • LBS-008
  • 其他(Gildeuretinol)

第6章 全球斯塔加特氏症藥物市場:依年齡層別,2018-2030

  • 兒童(17歲以下)
  • 成人(17歲以上)

第7章 全球斯塔加特氏症藥物市場:依配銷通路分類,2018-2030

  • 醫院藥房
  • 零售藥房
  • 網路藥房

第8章 全球斯塔加特病藥物市場:依地區分類,2018-2030

  • 北美洲
  • 美國
  • 加拿大
  • 歐洲
  • 英國
  • 德國
  • 義大利
  • 法國
  • 西班牙
  • 俄羅斯
  • 其他歐洲國家
  • 亞太地區
  • 中國
  • 印度
  • 日本
  • ASEAN
  • 澳洲
  • 韓國
  • 其他亞太地區
  • 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 其他拉丁美洲
  • 中東
  • GCC
  • 以色列
  • 其他中東地區
  • 非洲
  • 北非
  • 中部非洲
  • 南非

第9章 競爭形勢

  • 公司簡介
    • Kubota Pharmaceutical Holdings Co., Ltd.
    • Stargazer Pharmaceuticals Inc.
    • Iveric Bio, Inc.
    • Sanofi SA
    • Alkeus Pharmaceuticals Inc.
    • Astellas Pharma Inc.
    • CHABiotech CO., Ltd
    • ReVision Therapeutics, Inc.
    • Lin BioScience, Inc.
    • Biogen Inc.
    • F.Hoffmann-La Roche AG
    • Ocugen, Inc.
    • Ascidian Therapeutics
    • Nanoscope Therapeutics Inc.
    • Aequus Pharmaceuticals Inc.
    • Fera Pharmaceuticals, LLC
    • Insmed Incorporated
    • Belite Bio, Inc.
    • SpliceBio

第10章 章

  • 參考
  • 調查方法
簡介目錄
Product Code: CMI1314

Global stargardt disease therapeutics market is estimated to be valued at US$ 213.5 Mn in 2023, and is expected to exhibit a CAGR of 31.7% during the forecast period (2023-2030).

Report Coverage Report Details
Base Year: 2022 Market Size in 2023: US$ 213.5 Mn
Historical Data for: 2018 to 2021 Forecast Period: 2023 - 2030
Forecast Period 2023 to 2030 CAGR: 31.70% 2030 Value Projection: US$ 1,467.2 Mn
Global Stargardt Disease Therapeutics Market Share (%), By Drug Type, 2023
Stargardt Disease Therapeuticss Market - IMG1

Stargardt disease is a genetic condition that is caused by a tiny alteration in a single gene. It is also known as fundus flavimaculatus, and is the most common form of macular dystrophy. It affects approximately one in 10,000 people and affects both males and females. Stargardt causes a wasting of a central area of the retina called the macula. This area is eventually surrounded by a ring of white or yellow spots. An important layer of the retina, the retinal pigment epithelium (RPE), is also affected by an accumulation of 'waste' material called lipofuscin. Being diagnosed with Stargardt disease can be distressing, but with the right information and support, people can cope very well. It is important to remember that in the vast majority of cases, patients with stargardt disease do not lose all their sight. Stargardt disease usually affects central vision only. Peripheral vision is not usually affected. There is a great deal of research going on into potential treatments. Thus, introduction of such advanced treatment options in the market is expected to drive global stargardt disease therapeutics market growth over the forecast period.

Market Dynamics

The key players in the medical devices industry are focusing on the development of therapeutic drugs for various patient pool suffering from Stargardt disease. Thus, introduction of such advanced drugs in the market is expected to drive growth of the global stargardt disease therapeuticss market over the forecast period. For instance, on June 05, 2023, Alkeus Pharmaceuticals, a biopharmaceutical company, announced that the company had raised a US$ 150 million in Series B financing to support the registration and launch of gildeuretinol (ALK-001), a potential disease-modifying, precision medicine for the treatment of Stargardt disease, a leading genetic cause of blindness in children and young adults. The financing was led by Bain Capital Life Sciences, with additional participation by TCGX, Wellington Management and Sofinnova Investments.

Key features of the study:

  • This report provides an in-depth analysis of the global stargardt disease therapeuticss market and provides market size (US$ Mn) and compound annual growth rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
  • It profiles key players in the global stargardt disease therapeuticss market based on the following parameters- company highlights, products portfolio, key highlights, financial performance, and strategies.
  • Key companies covered as a part of this study include Kubota Pharmaceutical Holdings Co., Ltd., Stargazer Pharmaceuticals Inc., Iveric Bio, Inc., Sanofi S.A., Alkeus Pharmaceuticals Inc., Astellas Pharma Inc., CHABiotech CO., Ltd, ReVision Therapeutics, Inc., Lin BioScience, Inc., Biogen Inc., Hoffmann-La Roche AG, Ocugen, Inc., Ascidian Therapeutics, Nanoscope Therapeutics Inc., Aequus Pharmaceuticals Inc., Fera Pharmaceuticals, LLC, Insmed Incorporated, Belite Bio, Inc., and SpliceBio
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • Global stargardt disease therapeuticss market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global stargardt disease therapeuticss market

Detailed Segmentation:

  • Global Stargardt Disease Therapeuticss Market, By Drug Type:
    • Emixustat
    • LBS-008
    • Others (Gildeuretinol)
  • Global Stargardt Disease Therapeutics Market, By Age Group:
    • Children (Below 17 Years)
    • Adult (Above 17 Years)
  • Global Stargardt Disease Therapeutics Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Stargardt Disease Therapeutics Market, By Region:
    • North America
    • Latin America
    • Europe
    • Asia Pacific
    • Middle East
    • Africa
  • Company Profiles
    • Kubota Pharmaceutical Holdings Co., Ltd.
    • Stargazer Pharmaceuticals Inc.
    • Iveric Bio, Inc.
    • Sanofi S.A.
    • Alkeus Pharmaceuticals Inc.
    • Astellas Pharma Inc.
    • CHABiotech CO., Ltd
    • ReVision Therapeutics, Inc
    • Lin BioScience, Inc.
    • Biogen Inc.
    • Hoffmann-La Roche AG
    • Ocugen, Inc.
    • Ascidian Therapeutics
    • Nanoscope Therapeutics Inc.
    • Aequus Pharmaceuticals Inc.
    • Fera Pharmaceuticals, LLC
    • Insmed Incorporated
    • Belite Bio, Inc.
    • SpliceBio

Table of Contents

1. Research Objective and Assumption

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Drug Type
    • Market Snippet, By Age Group
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
    • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

    • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
    • Impact Analysis
    • Recent Test Launches
    • Epidemiology
    • Merger, Acquisition, and Collaborations
    • Regulatory Scenario
    • Key Developments
    • PEST Analysis
    • Epidemiology

4. Global Stargardt Disease Therapeutics Market - COVID-19 Impact Analysis

    • Economic Impact
    • COVID-19 Epidemiology
    • Impact on Supply and Demand

5. Global Stargardt Disease Therapeutics Market, By Drug Type, 2018-2030, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018-2030
    • Segment Trends
  • Emixustat
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
    • Segment Trends
  • LBS-008
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
    • Segment Trends
  • Others (Gildeuretinol)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
    • Segment Trends

6. Global Stargardt Disease Therapeutics Market, By Age Group, 2018-2030, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018-2030
    • Segment Trends
  • Children (Below 17 Years)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
    • Segment Trends
  • Adult (Above 17 Years)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
    • Segment Trends

7. Global Stargardt Disease Therapeutics Market, By Distribution Channel, 2018-2030, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018-2030
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)

8. Global Stargardt Disease Therapeutics Market, By Region, 2018-2030, (US$ Mn)

  • Introduction
    • Market Share Analysis, By Region, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, For Region, 2018-2030
    • Segment Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018-2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2018-2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Mn)
  • U.S.
  • Canada
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018-2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2018-2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Mn)
  • U.K.
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018-2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2018-2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Mn)
  • China
  • India
  • Japan
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018-2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2018-2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Mn)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018-2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2018-2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Mn)
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018-2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2018-2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Mn)
  • North Africa
  • Central Africa
  • South Africa

9. Competitive Landscape

  • Company Profiles
    • Kubota Pharmaceutical Holdings Co., Ltd.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Overview
  • Strategies
    • Stargazer Pharmaceuticals Inc.
    • Iveric Bio, Inc.
    • Sanofi S.A.
    • Alkeus Pharmaceuticals Inc.
    • Astellas Pharma Inc.
    • CHABiotech CO., Ltd
    • ReVision Therapeutics, Inc.
    • Lin BioScience, Inc.
    • Biogen Inc.
    • F.Hoffmann-La Roche AG
    • Ocugen, Inc.
    • Ascidian Therapeutics
    • Nanoscope Therapeutics Inc.
    • Aequus Pharmaceuticals Inc.
    • Fera Pharmaceuticals, LLC
    • Insmed Incorporated
    • Belite Bio, Inc.
    • SpliceBio

10. Section

  • References
  • Research Methodology
  • About us and Sales Contact